BioSpace News Archive

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Lawrence T. Kennedy, Jr. to the Company’s Board of Directors and Audit Committee of the Board effective January 3, 2023.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV-K Vaccination and Epigenetic modulation) under the Eurostars-3 program.

Oncocyte Corporation, a precision diagnostics company, announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets.

Aptorum Group Limited announced the completion of a private offering of USD$3 million aggregate principal convertible note due in December 2023, to be used towards the Company’s daily operations and clinical program.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection (PROFILE).

Heart Test Laboratories, Inc.d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) today provided a business update and reported financial results for the fiscal 2023 second quarter ended October 31, 2022.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced topline data from its National Institute of Health (NIH)-sponsored Phase 2 clinical trial of Bryostatin-1 for the treatment of advanced Alzheimer’s disease.

On Jan. 26, 2023, the U.S. Food and Drug Administration will hold a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward.

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business.